Search from the table of contents of 2.5 million books
Advanced Search (Beta)
Home > Congestive Heart Failure: Proceedings of the Symposium on New Drugs and Devices October 30–31, 1986, Philadelphia, Pennsylvania > What the FDA Requires for Endpoint Measures in Congestive Heart Failure Studies
Congestive Heart Failure: Proceedings of the Symposium on New Drugs and Devices October 30–31, 1986, Philadelphia, Pennsylvania |
J. Morganroth; E. Neil Moore
Springer US
Congestive Heart Failure: Proceedings of the Symposium on New Drugs and Devices October 30–31, 1986, Philadelphia, Pennsylvania
What the FDA Requires for Endpoint Measures in Congestive Heart Failure Studies
Authors

Raymond John Lipicky

ARI Id

1664674692772_2679395

Access

Not Available Free

Pages

151-153

DOI

10.1007/978-1-4613-2077-7_11

Chapter URL

https://rd.springer.com/chapter/10.1007/978-1-4613-2077-7_11

Table of Contents of Book
Showing 1 to 20 of 31 entries
Chapters/HeadingsAuthor(s)PagesInfo
Front Matter
i-xiii
Front Matter
1-1
The Public Health and Clinical Implications of the National Increase in Congestive Heart Failure
S. Yusuf; T. Thom; J. Probstfield
3-7
Therapeutic Endpoints in the Treatment of Congestive Heart Failure with Systolic Dysfunction
E. H. Sonnenblick; T. H. Lejemtel
9-16
Evaluation of Ventricular Function in Patients with Heart Failure: Invasive or Noninvasive?
Bertram Pitt
17-23
Assessment of Neurohormonal Parameters in Congestive Heart Failure: Determination of Sodium and Water Regulation
R. J. Cody
25-37
The Assessment of Quality of Life and Exercise Response in Patients with Chronic Cardiac Failure
Mariell Jessup
39-49
Back Matter
50-67
Front Matter
69-69
Animal Models of Heart Failure
Stewart J. Ehrreich
71-96
Electrophysiology in Congestive Heart Failure Animal Models
C. William Balke; Joseph F. Spear; E. Neil Moore
97-103
Noninvasive Evaluation of Proarrhythmia
J. Morganroth
105-115
Criteria for Proarrhythmia in Patients with Congestive Heart Failure: Use of Electrophysiologic Testing
Leonard N. Horowitz
117-130
Back Matter
131-140
Front Matter
141-141
Are Placebo-Controlled Trials Necessary in the Evaluation of New Therapeutic Agents in Severe Chronic Heart Failure?
Milton Packer
143-149
What the FDA Requires for Endpoint Measures in Congestive Heart Failure Studies
Raymond John Lipicky
151-153
Design of Trials to Assess Safety and Effectiveness in Rx of CHF
Robert Temple
155-170
Back Matter
171-174
Front Matter
175-175
Chapters/HeadingsAuthor(s)PagesInfo
Showing 1 to 20 of 31 entries
Similar Books
Similar Chapters
Similar Thesis

Similar News

Similar Articles
Similar Article Headings